

BromSite[®] (bromfenac) – First-time generic

- On February 13, 2024, <u>Lupin launched</u> an <u>AB-rated</u> generic version of Sun's <u>BromSite</u> (<u>bromfenac</u>) 0.075% ophthalmic solution.
 - In addition, Sun launched an authorized brand alternative of BromSite.
- BromSite is approved for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.
- Bromfenac is also available generically as a <u>0.09% ophthalmic solution</u> and <u>0.07% ophthalmic solution</u>.
 - Both these formulations carry similar indications as BromSite.
- According to IQVIA, BromSite had estimated annual sales in the U.S. of \$15 million as of December 2023.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.